FREE SHIPPING ON ORDERS $250+

Peptide Stock Solution Concentration: A Laboratory Reference

A stock solution's concentration is the mass of compound actually present divided by the final volume. For a certificated lot, the best available estimate of that mass is the laboratory's reported net content, not the label. Across 19 single-compound laboratory certificates, reported content ranged from 90.1 % to 116.3 % of the label. This reference covers mass concentration, molarity, dilution and the measurement steps that move a real solution away from its calculated value.

Precise Pep Labs Research Editorial Team · November 13, 2026 · 16 min read

Key facts

  • Concentration is mass divided by final volume; for a lyophilised lot, the reported net content on its certificate is a better estimate of the mass present than the label claim.
  • Across 19 single-compound analytical reports, reported net content ranged from 90.1 % to 116.3 % of the label (median 102.7 %); 7 were below the label and 12 above it.
  • On the 11 certificates that report two vials separately, the two vials differed by 0.7 % to 3.3 % of their mean, so a certificate figure is an estimate for any other vial, not a measurement of it.
  • Net content is used as reported, without multiplying by HPLC purity: whether such an adjustment is appropriate depends on each laboratory's reporting basis and calibration, and no certificate in the set documents a basis that calls for it.
  • A blend's total content cannot give the concentration of any one component; in one blend, a total at 105.1 % of label combined components at 97.6 % and 112.6 %.
Research use only. This article is reference material for laboratory research. It does not describe or recommend any human or veterinary use, dosing or administration, and nothing here is medical advice. Precise Pep Labs materials are sold for in vitro research only.

The short answer

The concentration of a stock solution is the mass of compound actually present divided by the final volume of the solution. For a lyophilised peptide, the best available estimate of that mass is usually the net content reported on the laboratory certificate for the lot, not the amount printed on the label. Molar concentration then follows from the molecular weight, and working solutions follow from the dilution relation C₁V₁ = C₂V₂.

Every one of those figures is an estimate with an uncertainty attached. This reference sets out the arithmetic, shows how far reported content sat from the label across 19 single-compound laboratory certificates we hold, and lists the measurement steps that move a real solution away from its calculated value.

This is a laboratory and analytical reference for research-use-only materials. It describes solutions prepared for in vitro and analytical work, and it contains no information about use in people or animals.

Six quantities that are easy to confuse

Several different numbers sit behind any concentration figure, and they answer different questions.

QuantityWhat it isWhere it comes from
Nominal label claimThe amount the vial is sold as, for example "10 mg"The label; a nominal value, not a measurement
Reported analytical net contentThe mass of the target compound the laboratory measured in the vials it testedThe certificate of analysis for the lot
HPLC purityThe target compound's share of the total chromatographic peak area [1]The certificate; a ratio, not a mass
Estimated concentrationMass divided by volume, calculated on paper under stated assumptionsArithmetic
Measured solution concentrationThe concentration of a prepared solution, determined by an analytical method on that solutionAn assay of the solution itself
Measurement uncertaintyThe range within which the true value is reasonably expected to lie [2]Combined from every step that contributes error

Our guide to peptide purity versus net content covers the difference between the second and third rows in detail. Here the point is narrower: a concentration calculated from a certificate is an estimated concentration. Only an assay of the prepared solution gives a measured one.

Should HPLC purity be multiplied by net content?

It is tempting to multiply the reported net content by the HPLC purity to "correct" for impurities. Whether that is appropriate depends on the laboratory's reporting basis: what the content figure was calibrated against, and whether impurities were already excluded when it was calculated. The certificates in our set document that basis to different degrees.

  • Axiom Analytics states that net peptide content is determined by quantitative HPLC against a reference standard. If the target compound's own peak is quantified against a calibrated standard of that compound, impurity peaks do not contribute to the result, and a further purity correction would remove them a second time. The certificate names the method but does not set out the calculation, so that reading is an inference, not something the certificate states.
  • KMD Analytical reports content as milligrams of net peptide per vial, from HPLC with diode-array detection, and states on the certificate that chromatographic purity "is not a measure of net peptide mass content". It does not say whether the content figure is already corrected for impurities.
  • The Kovera Labs and Freedom Diagnostics certificates in our set do not describe their content method in enough detail to say either way.

Because no certificate in the set documents a basis that calls for a purity adjustment, every calculation in this article uses the reported net content as reported, unadjusted. Where the basis matters to an experiment, the laboratory that issued the certificate is the source to ask.

How far reported content sat from the label: 19 single-compound analytical reports

To show why the label is a poor basis for a concentration, we compared reported net content with the label claim on our own certificates.

Population. Our catalog has 29 active products. Two of them, Research Water 10mL and 30mL, are solvents whose certificates report no net content, so they were never part of the population. That leaves 27 products, each with a most recent purity certificate reporting net content; all 27 certificates were read from the PDF itself, not from a database summary.

Inclusion criteria. One certificate per product, the most recent on file. Single-compound peptide products only.

Excluded from the 27, with reasons (8):

  • Five multi-component blends (BPC-157 + TB-500 10mg and 20mg, CJC-1295 (no DAC) + Ipamorelin 10mg, Glow 70mg, Klow 80mg). A blend's total content is the sum of several compounds with different molecular weights, so it cannot be pooled with single-compound figures. Blends are discussed separately below.
  • Two products that are not peptides: B12 10mg (cyanocobalamin) and NAD+ 1000mg, whose certificate describes a buffered formulation that we have not been able to confirm.
  • One product whose report could not be tied to a lot: GHK-Cu 100mg. The available report-to-product lot association could not be confirmed for this analysis, so the product is left out pending that confirmation. The exclusion says nothing about the result itself.

Included: 19 certificates (27 − 5 − 2 − 1).

Product (catalog name)Label claimReported net content% of labelLaboratoryLaboratory report IDCertificate dateVials measured
Tesa 10mg10 mg9.01 mg90.1 %Kovera LabsKVR-2026-B18B2A29 Jul 20261
Thymosin Alpha-1 10mg10 mg9.22 mg92.2 %KMD AnalyticalPPL-20261102-X2NF-012 Nov 20261
MOTS-c 10mg10 mg9.41 mg94.1 %Freedom DiagnosticsAccession 260720074722 Jul 20262
Glutathione 1500mg1500 mg1423.37 mg94.9 %Kovera LabsKVR-2026-4AD12C9 Aug 20262
PPL-3RT 10mg10 mg9.76 mg97.6 %Kovera LabsKVR-2026-7E645020 Jul 20261
PPL-2S31 50mg50 mg49.13 mg98.3 %KMD AnalyticalPPL-20261102-PTY3-012 Nov 20261
BPC-157 10mg10 mg9.90 mg99.0 %KMD AnalyticalPPL-20261102-EN8V-012 Nov 20261
Ipamorelin 10mg10 mg10.01 mg100.1 %Kovera LabsKVR-2026-DA19DB28 Jul 20261
PPL-2TR 20mg20 mg20.27 mg101.4 %Axiom AnalyticsAX-2026-1429-RQCQ6 Sep 20262
PPL-3RT 30mg30 mg30.82 mg102.7 %Axiom AnalyticsAX-2026-3619-QCR26 Sep 20262
MT-2 10mg10 mg10.29 mg102.9 %Axiom AnalyticsAX-2026-4427-JTGH6 Sep 20262
KPV 5mg5 mg5.17 mg103.4 %Freedom DiagnosticsAccession 260720074522 Jul 20262
IGF-1 LR3 1mg1 mg1.04 mg104.0 %Kovera LabsKVR-2026-4E6B709 Aug 20262
MOTS-c 40mg40 mg42.00 mg105.0 %Kovera LabsKVR-2026-03D3EE9 Aug 20262
PPL-3RT 20mg20 mg21.17 mg105.9 %Axiom AnalyticsAX-2026-3075-YX7K15 Oct 20262
MT-1 10mg10 mg10.76 mg107.6 %Axiom AnalyticsAX-2026-3726-DTEU6 Sep 20262
Semax 10mg10 mg10.81 mg108.1 %Kovera LabsKVR-2026-433CF418 Jul 20261
Selank 10mg10 mg11.61 mg116.1 %Kovera LabsKVR-2026-78418E20 Jul 20261
GHK-Cu 50mg50 mg58.15 mg116.3 %Freedom DiagnosticsAccession 260720075122 Jul 20262

The report IDs identify laboratory documents. They are not lot numbers and should not be read as such. Where a certificate reports two vials, the figure shown is the laboratory's own reported mean.

What the 19 certificates show:

  • Reported content ranged from 90.1 % to 116.3 % of the label claim, with a median of 102.7 %.
  • 10 of 19 fell between 95 % and 105 % of the label; 17 of 19 fell between 90 % and 110 %.
  • 7 were below the label and 12 above it. The deviation runs in both directions, so no single correction factor applies across products.

What they do not show. The four laboratories use different methods and different acceptance criteria. KMD states a specification of at least 90 % of the label claim; Axiom states that every vial must be within ±10 % of the label with a coefficient of variation no greater than 5 %; the Kovera certificates print a nominal reference such as "~10mg" with no numeric tolerance; and the Freedom certificates print no acceptance criterion. Pooling the results is therefore a description of these 19 documents, not a measure of any laboratory's accuracy, and this article does not describe any individual result as passing or failing. Our guide to reading a certificate of analysis explains each certificate field.

Two vials, two numbers

Eleven of the 19 certificates report each of two vials separately. On those certificates, the two vials differed by between 0.7 % and 3.3 % of their mean (median 1.5 %). The widest pair was GHK-Cu 50mg, at 57.19 mg and 59.10 mg.

Two vials are too few to estimate how much content varies across a whole lot. They do show, directly, that two vials from the same submission were not identical, which is the practical reason a certificate figure is an estimate for any other vial rather than a measurement of it.

What the laboratories say a result covers

The certificates themselves limit what their numbers mean. KMD's states that its results "apply solely to the specific sample as received from the client; they do not necessarily represent other units, lots, or production runs", and that client-supplied information, including the label claim and lot number, "is reported as provided and was not independently verified". Axiom's states that, unless it performed or witnessed the sampling, "the laboratory does not attest that the submitted sample represents the wider lot or batch". Freedom Diagnostics describes its analysis as "specific to the sample(s) provided".

A reported net content is therefore the laboratory's measurement of the vials it received. It is the best available estimate for the lot, not an exact statement of what any other vial contains.

Mass concentration: the arithmetic

Mass concentration is mass divided by volume:

concentration (mg/mL) = mass of compound (mg) / final volume of solution (mL)
1 mg/mL = 1 µg/µL = 1 g/L

The mass in that equation should be the mass actually present, which for a certificated lot means the reported net content rather than the label claim.

"Final volume" means the volume of the finished solution. Dissolving a solid adds some volume of its own, which is negligible for a few milligrams in a millilitre but not for large masses in small volumes; preparing the solution to a mark in volumetric glassware avoids the question.

How a label-based figure inherits the deviation. If the label is used in place of the reported content, the calculated concentration is wrong by the ratio between them:

relative error of a label-based estimate = (label claim / reported content) − 1

For the certificate reporting 90.1 % of its label, a label-based concentration is 11.0 % too high. For the certificate reporting 116.1 %, it is 13.9 % too low. Every dilution prepared from that stock carries the same relative error forward.

From mass concentration to molarity

Cell-based and binding assays are usually designed in molar terms, because molar concentration counts molecules rather than mass. The conversion uses the molecular weight:

molar concentration (mol/L) = mass concentration (g/L) / molecular weight (g/mol)
1.000 mg/mL = 1.000 g/L, so 1.000 mg/mL ÷ MW (g/mol) × 1000 = concentration in mM

Worked at 1.000 mg/mL, with molecular weights from the public PubChem records:

CompoundMolecular formulaMolecular weight (g/mol)1.000 mg/mL equals
Glutathione [3]C10H17N3O6S307.333.254 mM
KPV (Lys-Pro-Val) [4]C16H30N4O4342.432.920 mM
Ipamorelin [5]C38H49N9O5711.91.405 mM

Two cautions apply to the molecular weight.

Use the molecular weight that matches the mass. Trifluoroacetate (TFA) is almost always present in commercially synthesised peptides, and a common exchange step replaces it with chloride [6]; either way, the solid is a salt of the peptide rather than the peptide alone. A weighed mass of powder includes those counter-ions and any residual water, so it would need the molecular weight of the salt form, which is rarely known exactly. A reported net peptide content refers to the peptide alone, so it pairs with the molecular weight of the free peptide, which is what PubChem lists. Mixing the two bases introduces an error that can easily exceed the deviations in the table above.

Confirm the record matches the compound. The Ipamorelin certificate in our set prints the molecular formula C38H49N9O5, which matches the PubChem record [5]. Where a certificate prints no formula, or a variant of the compound is involved (acetylated or amidated forms, for example), the molecular weight should be checked against the exact structure.

Diluting to a working concentration

A working solution is prepared from a stock by dilution. The amount of solute does not change, so concentration and volume are inversely related:

C₁ × V₁ = C₂ × V₂
C₁ = stock concentration      V₁ = volume of stock taken
C₂ = target concentration     V₂ = final volume of the working solution

Worked example (generic). To prepare 1.000 mL of a 10.0 µM working solution from a 1.000 mM stock:

V₁ = (10.0 µM × 1.000 mL) / 1000 µM = 0.0100 mL = 10.0 µL
diluent = 1.000 mL − 0.010 mL = 0.990 mL (990 µL)

A small transfer magnifies any fixed volume error: an error of 0.1 µL is 1 % of a 10 µL transfer but only 0.1 % of a 100 µL transfer. A serial dilution spreads the work across larger, more reliable transfers: 100 µL of the 1.000 mM stock into 900 µL of diluent gives 100 µM, and 100 µL of that into 900 µL gives 10.0 µM. Each step is a 1:10 dilution, and each transfer volume is ten times larger than in the single-step version.

Where the remaining uncertainty comes from

Measurement uncertainty is the dispersion of values that could reasonably be attributed to the quantity being measured [2]. For a prepared solution, it is built up from every step, and the analytical-chemistry guidance on quantifying it counts weighing and volumetric operations among the standard contributors [9].

Volume. Pipettes, burettes and dispensers are covered by the international standard series ISO 8655, whose first part sets out terminology, general requirements and user recommendations for piston-operated volumetric apparatus, with later parts covering specific apparatus and the reference procedures for determining delivered volume [7]. The practical consequence is that a pipette's delivered volume is specified and verified by calibration, so the volume actually delivered at the setting used is one component of the uncertainty, not a given.

Mass. Where a solution is prepared from a weighed solid rather than from a whole vial, the balance contributes its own uncertainty. The United States Pharmacopeia distinguishes a mandatory chapter on balances, which applies when a procedure calls for a quantity to be "accurately weighed", from an informational chapter on weighing practice; both regard a balance's minimum weight as specific to the individual balance and derived from its measured repeatability [8].

Loss to surfaces. Peptides can adsorb to the walls of the containers that hold them. In one study, three cationic membrane-active peptides (mastoparan X, melittin and magainin 2) were measured by analytical HPLC, and at typical experimental concentrations 90 % or more could be lost from solution to the walls of common glass and plastic sample containers [10]. A second study incubated eight radiolabelled endocrine peptides for 48 hours in glass and plastic tubes and found important differences in recovery between surfaces; siliconisation decreased recovery, while adding 1 % bovine serum albumin improved it [11]. Both findings concern the specific peptides tested, and the size of the effect differs from compound to compound. The general lesson is that a dilute solution can lose a meaningful fraction of its solute to the container, and that the loss is proportionally largest at low concentration.

Incomplete dissolution and aggregation. A calculated concentration assumes all of the solid has dissolved and stays dissolved. A review of peptide physical stability lists sequence, concentration, pH, net charge, excipients, surfaces and interfaces, impurities, temperature, agitation and lyophilisation among the factors that influence aggregation [12]. Solubility is therefore a property of the particular compound and solution, not of peptides in general.

Combining the contributions. The certificate's reported content, the volume delivered, any weighing, surface loss and dissolution each add uncertainty, and the combined uncertainty of the final concentration is larger than any single contribution [2][9]. When the actual concentration matters to an experiment, the only way to know it is to measure the prepared solution.

Solvents and stability are compound-specific

No single solvent or storage condition is right for every peptide. A broad review of protein pharmaceutical stability discusses chemical and physical instability separately and distinguishes stabilisation in aqueous solution from the dried state [13], and the peptide-specific review above makes the same point about aggregation [12].

One example shows how a common solvent choice can matter. Bacteriostatic water is water preserved with 0.9 % benzyl alcohol. In studies of a single recombinant protein, human interleukin-1 receptor antagonist, reconstitution of the lyophilised protein with 0.9 % benzyl alcohol caused more aggregation than reconstitution with water [14], and benzyl alcohol accelerated aggregation in aqueous solution by binding weakly to the protein and favouring partially unfolded forms [15]. Those findings concern one recombinant protein, not a short synthetic peptide, and they cannot be assumed to apply to any particular peptide. They are cited here only as evidence that the solvent is an experimental variable, to be chosen and controlled for the compound in question.

Blends: why a total content cannot give each component's concentration

A blend certificate's headline net content is the sum of several compounds. A single total cannot establish the concentration of any one component, and a blend has no single molecular weight, so a molar concentration can only be calculated per component, from that component's own reported content and its own molecular weight.

All five blend certificates in our set report content component by component. The two Kovera Labs blend certificates also print a labelled amount for each component, which shows why a total can mislead:

Blend (catalog name)Laboratory report IDComponentLabelledReported% of label
BPC-157 + TB-500 20mgKVR-2026-1ED094 (certified 28 Jul 2026)BPC-15710 mg9.76 mg97.6 %
"TB-500(TB-4)", as printed10 mg11.26 mg112.6 %
Total20 mg21.02 mg105.1 %
CJC-1295 (no DAC) + Ipamorelin 10mgKVR-2026-02AD9E (certified 20 Jul 2026)Ipamorelin5 mg4.99 mg99.8 %
CJC-1295 (no DAC)5 mg5.04 mg100.8 %
Total10 mg10.03 mg100.3 %

In the first blend, the total sits at 105.1 % of the label while its two components sit at 97.6 % and 112.6 %. Offsetting deviations can hide inside a total that looks close to nominal. The per-component figures are only as reliable as the laboratory's ability to separate and quantify each compound, which is why a blend certificate's per-component method matters as much as its headline number. Our Klow blend guide walks through a four-component certificate in detail.

Limitations

  • One certificate per product. Each row in the main table is one laboratory submission. It describes the vials tested, not every vial in the lot.
  • Two vials at most. Where per-vial figures exist, two values cannot estimate lot-wide variability.
  • Different methods and criteria. The four laboratories document their content methods and acceptance criteria differently, and two do not document a numeric tolerance at all.
  • Not every certificate records a lot. Several certificates in the set print no lot identifier, so the report ID identifies the document, not the material.
  • Free-peptide molecular weights. The molar conversions use PubChem molecular weights for the free compounds, which pair with net content, not with gross powder mass.
  • Arithmetic is not a validated method. The calculations here are estimates under stated assumptions. A measured solution concentration requires an analytical determination.
  • Sources read. Studies were checked against their published abstracts and bibliographic records; the ISO and USP references were confirmed from the standards bodies' catalogue and guidance listings, not from the full standards.

Where to find the certificates

Every certificate in the main table is listed in the evidence section below and in our COA Library. The evidence section identifies each certificate by the date it was added to the library, which can differ from the certificate's own date shown above. If the certificate for a lot is not listed, contact us with the lot details and we will locate it.

Evidence from our lab reports

Each row is one certificate on file, identified by product and report date. Values are the figures the testing laboratory reported for that lot; they are not re-measured or adjusted here. "Latest COA in Library" and "Earlier COA" describe the certificate's place in the COA Library for that product. The lot currently shipping is identified by each product's inventory batch number, not by which certificate is newest.

ProductReport dateTestPurityNet contentCertificate
Tesa 10mgLatest COA in LibraryAug 5, 2026HPLC purity99.38%9.01 mg View
Thymosin Alpha-1 10mgLatest COA in LibraryNov 4, 2026HPLC purity99.99%9.22 mg View
MOTS-c 10mgLatest COA in LibraryAug 5, 2026HPLC purity99.44%9.41 mg View
Glutathione 1500mgLatest COA in LibraryAug 30, 2026HPLC purity99.40%1423.37 mg View
PPL-3RT 10mgLatest COA in LibraryAug 5, 2026HPLC purity99.75%9.76 mg View
PPL-2S31 50mgLatest COA in LibraryNov 3, 2026HPLC purity99.99%49.13 mg View
BPC-157 10mgLatest COA in LibraryNov 3, 2026HPLC purity99.99%9.90 mg View
Ipamorelin 10mgLatest COA in LibraryAug 5, 2026HPLC purity99.76%10.01 mg View
PPL-2TR 20mgLatest COA in LibrarySep 6, 2026HPLC purity99.92%20.27 mg View
PPL-3RT 30mgLatest COA in LibrarySep 9, 2026HPLC purity99.65%30.82 mg View
MT-2 10mgLatest COA in LibrarySep 6, 2026HPLC purity99.76%10.29 mg View
KPV 5mgLatest COA in LibraryAug 5, 2026HPLC purity99.05%5.17 mg View
IGF1-LR3 1mgLatest COA in LibraryAug 22, 2026HPLC purity99.78%1.04 mg View
MOTS-c 40mgLatest COA in LibraryAug 30, 2026HPLC purity99.57%42.00 mg View
PPL-3RT 20mgLatest COA in LibraryOct 15, 2026HPLC purity99.46%21.17 mg View
MT-1 10mgLatest COA in LibrarySep 6, 2026HPLC purity99.92%10.76 mg View
Semax 10mgLatest COA in LibraryAug 5, 2026HPLC purity99.52%10.81 mg View
Selank 10mgLatest COA in LibraryAug 5, 2026HPLC purity99.11%11.61 mg View
GHK-Cu 50mgLatest COA in LibrarySep 6, 2026HPLC purity99.88%58.15 mg View

Frequently asked questions

How is the concentration of a peptide stock solution calculated?
Divide the mass of compound actually present by the final volume of the solution: concentration in mg/mL equals mass in mg divided by volume in mL, and 1 mg/mL is the same as 1 µg/µL or 1 g/L. For a lyophilised lot with a certificate of analysis, the reported net content is a better estimate of the mass present than the label claim. The result is an estimated concentration; only an analytical measurement of the prepared solution gives a measured one.
Should the label amount or the reported net content be used?
The reported net content, where a certificate provides one. Across 19 single-compound laboratory certificates we hold, reported content ranged from 90.1 % to 116.3 % of the label claim. A concentration calculated from the label inherits that deviation: for a certificate reporting 90.1 % of label it is 11.0 % too high, and for one reporting 116.1 % it is 13.9 % too low. The reported figure is still an estimate for the lot, because laboratories measure only the vials submitted to them.
Should HPLC purity be multiplied by the net content?
Only if the laboratory's reporting basis calls for it. If content is quantified from the target compound's own peak against a calibrated reference standard, impurities are already excluded and a further purity correction would remove them twice; if content is measured on a different basis, an adjustment may be appropriate. The certificates in our set document their basis to different degrees and none documents a basis that calls for an adjustment, so this reference uses net content as reported.
How is mg/mL converted to molarity?
Divide the mass concentration in g/L by the molecular weight in g/mol to get mol/L; at 1.000 mg/mL, that is 1000 divided by the molecular weight, in mM. Using PubChem molecular weights, 1.000 mg/mL is 3.254 mM for glutathione (307.33 g/mol), 2.920 mM for KPV (342.43 g/mol) and 1.405 mM for ipamorelin (711.9 g/mol). The molecular weight must match the mass basis: net peptide content pairs with the free-peptide molecular weight, not with that of a salt form.
Why can a prepared solution's measured concentration differ from the calculated one?
Because each step adds uncertainty: the estimate of mass on the certificate, the volume actually delivered by a pipette, any weighing, incomplete dissolution or aggregation, and loss of peptide to container surfaces. Published studies have reported large losses of some peptides to glass and plastic at typical experimental concentrations, with the effect depending on the peptide and the surface. When the exact concentration matters, the prepared solution has to be measured.
How should the concentration of a blend be calculated?
Per component, from each component's own reported content and molecular weight. A blend's total content is a sum of different compounds, so it cannot establish the concentration of any one of them, and a blend has no single molecular weight. In one blend certificate in our set, the total was 105.1 % of label while its two components were 97.6 % and 112.6 % of their labelled amounts.

References

  1. United States Pharmacopeia. General Chapter <621> Chromatography. USP–NF. https://doi.usp.org/USPNF/USPNF_M99380_01_01.html
  2. JCGM 100:2008. Evaluation of measurement data: Guide to the expression of uncertainty in measurement (GUM 1995 with minor corrections). Joint Committee for Guides in Metrology, 2008. https://www.bipm.org/documents/20126/2071204/JCGM_100_2008_E.pdf
  3. PubChem Compound Summary for CID 124886, Glutathione (C10H17N3O6S; molecular weight 307.33). National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/124886
  4. PubChem Compound Summary for CID 125672, Lys-Pro-Val (C16H30N4O4; molecular weight 342.43). National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/125672
  5. PubChem Compound Summary for CID 9831659, Ipamorelin (C38H49N9O5; molecular weight 711.9). National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/9831659
  6. Andrushchenko VV, Vogel HJ, Prenner EJ. Optimization of the hydrochloric acid concentration used for trifluoroacetate removal from synthetic peptides. Journal of Peptide Science. 2007;13(1):37–43. doi:10.1002/psc.793
  7. ISO 8655-1:2022. Piston-operated volumetric apparatus — Part 1: Terminology, general requirements and user recommendations. International Organization for Standardization, 2022. https://www.iso.org/standard/68796.html
  8. United States Pharmacopeia. Frequently asked questions: <41> Balances and <1251> Weighing on an Analytical Balance. https://www.usp.org/frequently-asked-questions/balances-and-weighing-analytical-balance
  9. Eurachem/CITAC. Quantifying Uncertainty in Analytical Measurement, 3rd edition (QUAM:2012.P1). Ellison SLR, Williams A (eds), 2012. https://www.eurachem.org/images/stories/Guides/pdf/QUAM2012_P1.pdf
  10. Kristensen K, Henriksen JR, Andresen TL. Adsorption of cationic peptides to solid surfaces of glass and plastic. PLoS One. 2015;10(5):e0122419. doi:10.1371/journal.pone.0122419
  11. Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Analytical Biochemistry. 2011;414(1):38–46. doi:10.1016/j.ab.2011.02.009
  12. Zapadka KL, Becher FJ, Gomes dos Santos AL, Jackson SE. Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus. 2017;7(6):20170030. doi:10.1098/rsfs.2017.0030
  13. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research. 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6
  14. Roy S, Jung R, Kerwin BA, Randolph TW, Carpenter JF. Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations. Journal of Pharmaceutical Sciences. 2005;94(2):382–396. doi:10.1002/jps.20258
  15. Zhang Y, Roy S, Jones LS, Krishnan S, Kerwin BA, Chang BS, Manning MC, Randolph TW, Carpenter JF. Mechanism for benzyl alcohol-induced aggregation of recombinant human interleukin-1 receptor antagonist in aqueous solution. Journal of Pharmaceutical Sciences. 2004;93(12):3076–3089. doi:10.1002/jps.20219

How this article was checked

  • Written by: Precise Pep Labs Research Editorial Team
  • Last reviewed: November 13, 2026
  • Published: November 13, 2026
  • Last updated: November 13, 2026
  • Lab reports cited: 19
  • Sources: the numbered references above and the certificates of analysis in the COA Library. Editorial content is reviewed for research-use-only compliance before publication.